At the American Diabetes Association's Scientific Session in Boston, Dr. Vanita Aroda presented results that could fundamentally reshape how millions take their diabetes medication: a daily pill that works as well as injections. The drug, elecoglipron, belongs to a class of medications called GLP-1 receptor agonists, and for the first time, a rigorous clinical trial shows that an oral version—one that doesn't require the strict fasting protocols of existing pill alternatives—can meaningfully lower blood sugar and reduce body weight.
For people living with type 2 diabetes, this matters deeply. Most GLP-1 medications currently available require injections, a barrier that limits access and can deter patients from starting therapy. Semaglutide, the one GLP-1 pill on the market, demands an empty stomach and a 30-minute food-free window after taking it—constraints that complicate daily life. Oral medications that work without these restrictions could reach more people who need them.
The SOLSTICE trial tested elecoglipron across 406 participants with type 2 diabetes in nine countries, including the United States. After 26 weeks, the results were striking: up to 89.6% of people taking the medication achieved an HbA1c level of 7%, the standard target for average blood glucose control over two to three months. In the placebo group, only 24.9% reached this goal. The drug's effect on body weight was equally compelling—72.3% of participants in the treatment arms lost at least 5% of their body weight, compared to 20.2% in the placebo group. The medication demonstrated these benefits at all tested dose concentrations, and safety and tolerability aligned with what researchers see in other GLP-1 therapies at similar development stages.
Dr. Aroda, who directs Diabetes Clinical Research at Mass General Brigham's Division of Endocrinology, Diabetes & Hypertension, frames the significance clearly: oral formulations could bridge critical gaps in type 2 diabetes treatment. The current landscape forces a choice between the inconvenience of injections or the rigorous fasting requirements of the single available oral option. Elecoglipron, by contrast, offers the convenience of a daily pill with the flexibility patients actually need.
The trial was sponsored by AstraZeneca and published simultaneously in The Lancet, lending weight to findings that emerged from rigorous, placebo-controlled methodology. Researchers tested different starting doses, dose-escalation schemes, and maintenance regimens to understand which approach works best—the kind of careful design that builds clinicians' confidence in new therapies.
The timing of this breakthrough extends beyond elecoglipron alone. At the same ADA meeting, Aroda also presented positive results from REIMAGINE 1, a trial of CagriSema, a novel combination therapy pairing cagrilintide with injectable semaglutide. That study saw up to 87% of participants reach the HbA1c target of 7%, suggesting multiple pathways forward for improving diabetes outcomes.
What connects these advances is a shared vision: translating scientific progress into treatments that actually fit into people's lives. Oral medications that work without fasting protocols, combination therapies that amplify effectiveness, and expanded options all move toward the same goal of safer, more accessible diabetes care. For the millions managing type 2 diabetes, elecoglipron represents a step closer to a treatment that matches their needs, not the other way around.